Argos Therapeutics, Inc. Stock Price - ARGSQ

Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Argos Therapeutics, Inc. ARGSQ Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.00% 0.07 0.07 0.0458 0.0458 0.07 14:51:12
Bid Price Ask Price Spread Spread % News
0.06 0.07 0.01 14.29% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
8 12,853 $ 0.051927 $ 667 12,689 0.019 - 0.25
Last Trade Time Type Quantity Stock Price Currency
14:51:10 9,857 $ 0.07 USD

Argos Therapeutics, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 741.07k 10.59M $ -40.58M - -0.02 6.78M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Argos Therapeutics, Inc. News

Latest ARGSQ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARGSQ Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.0680.070.04540.06092k62k23k0.0022.94%
1 Month0.0570.0790.040.069431862k14k0.01322.81%
3 Months0.0640.090.040.0770202205k14k0.0069.38%
6 Months0.050.10450.0190.0600202307k23k0.0240.00%
1 Year0.180.250.0190.1086202410k37k-0.11-61.11%
3 Years0.220.30250.0190.15192022M52k-0.15-68.18%
5 Years0.220.30250.0190.15192022M52k-0.15-68.18%

Argos Therapeutics, Inc. Description

Argos Therapeutics is an immuno-oncology company that has been focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary precision immunotherapy technology platform called Arcelis.. Argos is developing an Arcelis-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients. Funding for the development of AGS-004 has been provided by the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and the Collaboratory of Research for AIDS Eradication.

Your Recent History
Argos Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.